First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2018
At a glance
- Drugs AdVAV (Primary)
- Indications Anthrax
- Focus Adverse reactions; First in man
- Sponsors Altimmune
- 28 Mar 2018 According to an Altimmune media release, first two cohorts have been enrolled in this trial.
- 22 Jan 2018 Status changed from not yet recruiting to recruiting.
- 11 Dec 2017 According to aN Altimmune media release, Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for NasoShield